Lisata Therapeutics Inc.
$ 4.01
-11.48%
15 Apr - close price
- Market Cap 40,916,300 USD
- Current Price $ 4.01
- High / Low $ 4.65 / 3.67
- Stock P/E N/A
- Book Value 1.68
- EPS -1.73
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.76 %
- 52 Week High 5.07
- 52 Week Low 1.81
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
Analyst Target Price
$9.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-01 | 2024-08-12 | 2024-05-09 | 2024-02-29 | 2023-11-02 | 2023-08-14 | 2023-05-09 |
| Reported EPS | -0.3344 | -0.49 | -0.54 | -0.55 | -0.55 | -0.59 | -0.61 | -0.65 | -0.66 | -0.65 | -0.5 | -0.77 |
| Estimated EPS | -0.625 | -0.59 | -0.64 | -0.53 | -0.76 | -0.77 | -0.76 | -0.72 | -0.89 | -0.93 | -0.7 | -0.81 |
| Surprise | 0.2906 | 0.1 | 0.1 | -0.02 | 0.21 | 0.18 | 0.15 | 0.07 | 0.23 | 0.28 | 0.2 | 0.04 |
| Surprise Percentage | 46.496% | 16.9492% | 15.625% | -3.7736% | 27.6316% | 23.3766% | 19.7368% | 9.7222% | 25.8427% | 30.1075% | 28.5714% | 4.9383% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LSTA
2026-04-13 01:38:43
This article announces that Lisata Therapeutics will be acquired by Kuva Labs for $4.00 per share in an all-cash transaction. The deal indicates a significant development for both companies' futures.
2026-04-04 22:40:49
Intellectia AI recommends "Hold" for Lisata Therapeutics Inc (LSTA) due to mixed technical indicators and significant declines in revenue and net income in Q4 2025. While moving averages are bullish, the negative MACD and weak financial performance suggest it's not a strong buy opportunity for long-term investors. A recent analyst rating from Brookline, however, maintained a "Buy" rating and raised the price target to $32, citing extended patent protection.
2026-04-03 13:39:48
Lisata Therapeutics Inc. and Kuva Labs have extended their equity acquisition offer deadline to April 13, 2026, as per a U.S. SEC filing. This extension allows more time for potential investors to assess the acquisition and reflects the parties' intent to finalize the agreement. The decision likely stems from various factors like market conditions or investor feedback, though no specific changes to terms have been disclosed.
2026-04-03 13:39:48
Lisata Therapeutics announced an extension to the deadline for Kuva Acquisition Corp. to commence its tender offer for Lisata Therapeutics' common stock, moving it to April 13, 2026. This follows a previous agreement where Kuva Labs plans to acquire Lisata for $5 per share in cash, plus a contingent value right of $1 per share based on regulatory milestones. Lisata Therapeutics has also regained full rights to its cancer drug candidate, certepetide, in Greater China.
2026-04-03 11:11:02
Lisata Therapeutics Inc. and Kuva Labs have extended their equity acquisition offer deadline to April 13, 2026, according to an SEC filing. This extension provides potential investors more time to evaluate and participate in the acquisition, reflecting the parties' continued good faith and allowing for further market response. The decision may be influenced by market conditions, investor feedback, or the need for more detailed transaction optimization.
2026-04-03 11:11:02
Lisata Therapeutics (LSTA) and Kuva Labs Inc. have agreed to postpone the commencement of Kuva's tender offer to acquire all outstanding Lisata common shares from April 3, 2026, to April 13, 2026. This extension was formalized through a waiver to their existing Agreement and Plan of Merger dated March 6, 2026. The filing emphasizes that the tender offer has not yet begun and advises Lisata stockholders to review the forthcoming Schedule TO and Schedule 14D-9 before making any decisions regarding their shares.
